2024-01-05 16:32:00 ET
Molecular Partners ( NASDAQ: MOLN ) has entered into a collaboration agreement with Orano Med to develop novel Radio-DARPin therapeutics, or RDTs, for the treatment of cancer.
Under the agreement, the companies will exclusively develop DLL3 as an RDT target. Molecular Partners will maintain the option to explore DLL3 for targeted therapies outside of the radiotherapy space. The agreement also covers other oncology targets, the companies said .
Molecular Partners and Orano plan to share the costs of preclinical and clinical development, with additional agreements being put in place for the development and commercialization of any candidates that move into the clinical stage.
More on Molecular Partners
- Seeking Alpha’s Quant Rating on Molecular Partners
- Historical earnings data for Molecular Partners
- Financial information for Molecular Partners
For further details see:
Molecular Partners, Orano to collaborate on RDT therapies for cancer